Clozapine for first-episode schizophrenia [4]

American Journal of Psychiatry

Volumn 159, Issue 2, 2002, Pages 317-

  Kolivakis, Theodore T ^a   Margolese, Howard C ^a   Beauclair, Linda ^a   Chouinard, Guy ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; GABAPENTIN; OLANZAPINE; PAROXETINE;

ADULT; CASE REPORT; CLINICAL TRIAL; CROSSOVER PROCEDURE; DEPRESSION; DYSKINESIA; HUMAN; LETTER; MALE; NEGATIVE SYNDROME; PARANOID SCHIZOPHRENIA; PARKINSONISM; PRIORITY JOURNAL; SUICIDAL BEHAVIOR; TREATMENT OUTCOME;

ADULT; CLOZAPINE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUICIDE, ATTEMPTED;

EID: 0036159621     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.159.2.317     Document Type: Letter

References (9)

1. Clozapine response in treatment-refractory first-episode schizophrenia
2. The use of clozapine in the treatment of aggressive schizophrenia
3. Gabapentin: Long-term antianxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders
4. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia
5. Reliability and validity of a depression rating scale for schizophrenics
6. The InterSePT Scale for Suicidal Thinking (ISST): A new assessment instrument for suicidal patients with schizophrenia
7. The Extrapyramidal Symptom Rating Scale
8. Should clozapine be a first-line treatment for schizophrenia? The rationale for a double-blind clinical trial in first-episode patients
9. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: Impact on risk-benefit assessment